Annual report pursuant to Section 13 and 15(d)

Corporate Information - Narrative (Details)

v3.22.0.1
Corporate Information - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2014
Subsequent Event [Line Items]      
Cash and cash equivalents $ 117,764 $ 70,436  
Net loss (45,738) (37,230)  
Accumulated deficit $ (257,144) $ (211,406)  
Pieris Pharmaceuticals GmbH      
Subsequent Event [Line Items]      
Ownership interest acquired (as a percent)     100.00%